Harvard Bioscience (HBIO) Stock: Buy, Sell, or Hold?
$9.96
+0.70 (+7.55%)
▲
5d:
+15.67%
30d:
+20.42%
90d:
+49.31%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (25%)
Quality Score
38/100
Position
EXTENDED
30-Day Fair Range
$8.11 – $8.91
Position: EXTENDED
Forward P/E & Valuation
14.4x
STRETCHED
vs 10.3x historical avg
Wall Street Target
$10.25
+10.7% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$8.11 / $9.60
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR BETTER ENTRY: HBIO is 11.8% above its trading range ($8.91). Market expects 11.9% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Get Alerted When HBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.31
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.78
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HBIO is currently trading at $9.96, which is considered extended relative to its 30-day fair value range of $8.11 to $8.91. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.4) compared to its historical average (10.3). At these levels, the market is pricing in 11.9% annual earnings growth.
Technical Outlook: Technically, HBIO is in a strong uptrend. The price is approaching resistance at $9.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: HBIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.25 (+10.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HBIO is in a strong uptrend. The price is approaching resistance at $9.60. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: HBIO scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.25 (+10.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.11 -
$8.91
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
24.8%
Trading Range & Key Levels
30-Day Trading Range
$8.11 -
$8.91
Current vs Trading Range
EXTENDED
Support Level
$8.11
Resistance Level
$9.60
Current Trend
Strong Uptrend
Technical data as of
Nov 10, 2026
Quantitative Signal Breakdown
- BEARISH: Price significantly overextended (+11.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.5%)
- BULLISH: Trading below Wall St target ($10.25)
- BULLISH: Expecting earnings turnaround to 11.9% growth with 11.1% revenue growth
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
14.36
Wall Street Target
$10.25
(+10.7%)
Revenue Growth (YoY)
11.1%
Earnings Growth (YoY)
-80.3%
Profit Margin
-11.9%
Valuation Premium vs History
+11.9% premium
PE vs Historical
14.4 vs 10.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.9%
(market-implied from PE analysis)
1-Year Target
$10.36
(+12%)
2-Year Target
$11.60
(+25%)
3-Year Target
$12.97
(+40%)
3-Yr Target (if PE normalizes)
(PE: 14→10)
PE COMPRESSION
$9.31
(+1%)
Earnings growth offset by PE compression
Share HBIO Analysis
Share this live HBIO analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (HBIO)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jun 30, 2026
Daily AI digest
AI Retail Discussion Summary:
A single bullish StockTwits message expresses optimism about the potential movement of $HBIO stock.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 1:25 PM ET
Data refreshes hourly during market hours. Next update: 2:25 PM
Data refreshes hourly during market hours. Next update: 2:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HBIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
STRONG BUY
34 analysts |
$486 | 40 SELL |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$82 | 44 HOLD |
|
RGEN
Repligen Corporation |
STRONG BUY
21 analysts |
$203 | 49 HOLD |
|
WST
West Pharmaceutical Serv… |
STRONG BUY
16 analysts |
$471 | 50 HOLD |
|
RMD
ResMed Inc |
HOLD
20 analysts |
$264 | 58 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive HBIO Research Pages
